Nuvectis Pharma Commences Underwritten Public Offering of Common Stock
NVCT has more than doubled off its 52-week low of $5.55 on elevated volume (2.5× avg).
Summary
Nuvectis Pharma announced the commencement of an underwritten public offering of its common stock, with all shares offered by the company and an option for underwriters to purchase an additional 15%. This offering is being made under an existing $150 million shelf registration. The capital raise follows the company's recent licensing agreement for two clinical-stage compounds, NXP100 and NXP200, in late June, and a Q1 net loss of $6.1 million with a $6.5 million cash burn reported in May. While the offering will dilute existing shareholders, it provides crucial funding to advance the company's development programs, particularly the newly acquired assets, and support general corporate purposes. The final terms and size of the offering will be disclosed in a forthcoming prospectus supplement.
At the time of this announcement, NVCT was trading at $28.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $756.8M. The 52-week trading range was $5.55 to $29.28. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.